This article was originally published on TipRanks.com Array Technologies, Inc.
Array Technologies has won a large contract with Primoris Services Corporation. Array, which manufactures ground-mounted systems and provides tracking solutions for solar energy …
There’s a new FDA-approved melanoma medication on the scene. Today, the U.
Analysts chime in across the Street on potential approval odds for TRVN’s pain management drug oliceridine and ARRY’s cancer combination therapy of encorafenib with binimetinib.
Array Biopharma (NASDAQ:ARRY) shares started the day lower in the wake of disappointing results from competitor Exelixis (NASDAQ:EXEL). Exelixis announced that its metastatic colorectal cancer (mCRC) treatment did …
Has this billion-dollar fund made the right call on ARRY, VRX, and HIMX?
Analyst expected NDA acceptance- but believes the FDA news importantly lowers regulatory risk for ARRY.
Forecasting a potential $500 million yearly sales opportunity ahead, the analyst lifts price target on Array.
Three key biopharma trades from the highly-successful $78 billion Renaissance fund
Array Biopharma Inc (NASDAQ:ARRY) shares are dipping almost 8% after the discouraging news broke that the biotech firm has decided to withdraw its …